Former Member of Congress joins Lung Cancer Alliance

Today, Lung Cancer Alliance (LCA) proudly announced that The Honorable Michael G. Oxley has agreed to join its Board of Directors.  Oxley, a former Member of Congress,  joins LCA, the only national organization dedicated solely to all those either living with or at risk for lung cancer, as it prepares to begin its sixth year of patient support and advocacy headquartered in Washington, DC.

"This is a very proud day for LCA and the entire lung cancer community," said Laurie Fenton Ambrose, LCA President & CEO.  "Mike Oxley is one of the most highly regarded and respected public policy leaders today, known for his integrity, dedication and devotion to sound polices and principles.  He has always put the needs of his constituents and this nation first when considering matters locally and globally and the lung cancer community is now poised to benefit from these same qualities as we pursue a more compassionate and comprehensive plan of action for lung cancer." 

Oxley is an attorney by profession.  He earned his B.A. from Miami University in 1966 and his law degree from The Ohio State University College of Law in 1969.  From 1969 to 1972, Oxley was a special agent for the Federal Bureau of Investigation.  From 1972 to 1981 he was elected to serve in the Ohio House of Representatives until a special election propelled him to Congress in 1981. Oxley represented Ohio's 4th District until his retirement from Congress in 2007.  He is currently Of Counsel at Baker Hostetler law firm in Washington, D.C., and senior advisor to the board of NASDAQ OMX Group, Inc.

Year after year, Oxley earned legislative awards for his wise use of taxpayer dollars.  He rose to become Chairman of the House Committee on Financial Services and promoted policies that encouraged personal savings, jobs and economic growth.   He is co-author of the Sarbanes-Oxley Act of 2002, which set new and enhanced existing standards for corporate governance and financial practices in response to a number of major corporate accounting scandals. 

"It wasn't until my lung cancer diagnosis that I became aware of the tremendous stigma and challenge facing this community, particularly in the areas of public health and policy," said Oxley.  "As a non-smoker, a lung cancer diagnosis was the farthest thing from my mind.  I want to help LCA reverse decades of neglect and misunderstanding, so that people living with the disease and those who may be diagnosed in the future can have better outcomes." 

Oxley joins a respected LCA Board of Directors roster which currently includes:

  • Jane Reese-Coulbourne, Partner, Advocate Partners, Arlington, VA
  • Adrienne R. Halper, Former Managing Director of Private Equity Funds, New York, NY
  • T. Joseph Lopez, Admiral, United States Navy, Retired, Annandale, VA
  • John M. Duff, Jr., Co-founder & Managing Director, Duff Ackerman and Goodrich, LLC, Washington, DC, San Francisco, CA
  • Cheryl Healton, Dr. PH, President & CEO, American Legacy Foundation, Washington, DC
  • Priscilla Dewey Houghton, Lung Cancer Survivor, Arts Advocate, Cohasset, MA
  • Secretary Norman Y. Mineta, Vice Chairman, Hill and Knowlton, Washington, DC
  • Deborah Morosini, MD, Principal Pathologist, AstraZeneca Pharmaceuticals, Sister of the late Dana Reeve, Weston, MA
  • James Mulshine, MD, Associate Provost for Research and Vice President for Research, Rush University, Chicago, IL
  • James Parles, MD, Fellow of the American Academy of Pediatrics, Smithtown, NY

SOURCE Lung Cancer Alliance


Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study shows AI can predict prognosis in triple-negative breast cancer